Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.

Daniela A BotaThomas H TaylorDavid E PiccioniChristopher M DumaRenato V LaRoccaSantosh KesariJose A CarrilloMehrdad AbediRobert D AikenFrank P K HsuXiao-Tang KongCandace HsiehPeter G BotaGabriel I NistorHans S KeirsteadRobert O Dillman

Published in: Journal of experimental & clinical cancer research : CR (2022)

NCT, NCT03400917 , Registered 10 January 2018.

Keyphrases

newly diagnosed
dendritic cells
end stage renal disease
chronic kidney disease
single cell
regulatory t cells
prognostic factors
clinical trial
bone marrow
mesenchymal stem cells
drug delivery
patient reported